<p>惡補科普知識讓教授對你刮目相看 <br />想 吸收新知 提升常識 不能錯過的Podcast <br />適合聽眾: <br /> 需要面試惡補的高中生、 <br /> 需要累積實力的國高中生、 <br /> 需要吸收新知的碩博士生、 <br /> 想要提升常識的普羅大眾 <br />美國加州大學博士以甜美嗓音提供你豐富的專業科普知識 <br /> <br />請我一杯咖啡，讓我持續創作吧！ <br />https://open.firstory.me/join/science-up <br /> <br />難易度: <br />國小程度 * <br />高中程度 *** <br />博士程度 ***** <br /> <br />#科普 #科普上層樓 #科學 #Science #Science-up #Pharma #科普Podcast <br /> <br/>Powered by <a href="https://firstory.me">Firstory Hosting</a></p>
Language
🇨🇳
Publishing Since
4/5/2021
Email Addresses
1 available
Phone Numbers
0 available
February 6, 2024
<p><strong>難易度: **</strong> <br /><strong>介紹新一波的研究正在揭示癌症和神經元之間的關係，並尋找可以阻止他們之間交流的方法。</strong> <br />#propranolol # calcitonin gene-related peptide, CGRP <br /> <br /><strong>請我喝杯咖啡吧</strong><a href="https://open.firstory.me/join/science-up" target="_blank"><strong>https://open.firstory.me/join/science-up</strong></a> <br />小額贊助支持本節目： <a href="https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1" target="_blank">https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1</a> <br />留言告訴我你對這一集的想法： <a href="https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1/comments" target="_blank">https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1/comments</a></p> <br /> <br/>Powered by <a href="https://firstory.me">Firstory Hosting</a>
January 31, 2024
<p><strong>難易度: ****</strong> <br /><strong>介紹:</strong> <br /><strong>輝瑞新冠口服藥Paxlovid (nirmatrelvir/ ritonavir)</strong> <br /><strong>鹽野義新冠特效藥 Xocova (ensitrelvir)</strong> <br /><strong>先諾欣XIANNUOXIN (simnotrelvir/ ritonavir)</strong> <br /><strong>#3C-like protease #3CL protease #Pfizer #Shionogi #Simcere #Molnupiravir #Lagevrio</strong> <br /> <br /><strong><em>Paxlovid:</em></strong> <br />Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science (2021); 374: 1586–1593. <br />N Engl J Med. (2022); 14, 386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16. <br /><strong><em>Xocova:</em></strong> <br />Tyndall, J. D. A. S-217622, a 3CL protease inhibitor and clinical candidate for SARS-CoV-2. J. Med. Chem. (2022); 65: 6496–6498. <br />Antimicrob Agents Chemother. (2022);18, 66(10): e0069722. doi: 10.1128/aac.00697-22. Epub 2022 Sep 13. <br /><strong><em>XIANNUOXIN: </em></strong> <br />Jiang, X., Su, H., Shang, W. et al. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. Nat Commun (2023); 14: 6463. <a href="https://doi.org/10.1038/s41467-023-42102-y" target="_blank">https://doi.org/10.1038/s41467-023-42102-y</a> <br />Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19 N Engl J Med (2024); 390: 230-241. DOI: 10.1056/NEJMoa2301425 <br /> <br /><strong>請我喝杯咖啡吧</strong><a href="https://open.firstory.me/join/science-up" target="_blank"><strong>https://open.firstory.me/join/science-up</strong></a> <br />小額贊助支持本節目： <a href="https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1" target="_blank">https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1</a> <br />留言告訴我你對這一集的想法： <a href="https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1/comments">https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1/comments</a></p> <br /> <br/>Powered by <a href="https://firstory.me">Firstory Hosting</a>
January 29, 2024
<p><strong>難易度: **</strong> <br /><strong>#化療 #掉髮 #TSLP #Thymic stromal lymphopoietin #CyclinD1 #Perseus Therapeutics</strong> #<strong>tezepelumab #Tezspire #AstraZeneca</strong> <br /><strong> </strong> <br /><strong>請我喝杯咖啡吧</strong><a href="https://open.firstory.me/join/science-up" target="_blank"><strong>https://open.firstory.me/join/science-up</strong></a> <br />小額贊助支持本節目： <a href="https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1" target="_blank">https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1</a> <br />留言告訴我你對這一集的想法： <a href="https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1/comments">https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1/comments</a></p> <br /> <br/>Powered by <a href="https://firstory.me">Firstory Hosting</a>
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.